Gold bars to be exempt from tariffs, White House clarifies
RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ:GCTK), a medical device company currently trading at $5.83 and identified as undervalued by InvestingPro analysis, announced Wednesday that David S. Hirsh, MD, has joined the company as Medical Director - Cardiology for its clinical advisory team, where he will provide strategic leadership for clinical and educational initiatives related to the company’s Continuous Blood Glucose Monitor (CBGM).
Dr. Hirsh, who currently serves as a cardiac electrophysiologist at Harbin Clinical Cardiology Rome since early 2025, brings extensive experience to the role. He previously worked as an Associate Professor of Medicine in the Division of Cardiology at Emory University School of Medicine and as Director of Clinical Cardiac Electrophysiology at Grady Memorial Hospital.
Glucotrack’s CBGM technology is designed as a long-term implantable system with no wearable component, intended to provide continuous blood glucose monitoring for up to three years. Unlike traditional monitoring systems that measure glucose from interstitial fluid, the company’s device measures glucose directly from blood. According to InvestingPro data, while the company maintains a healthy current ratio of 4.85 and holds more cash than debt, it faces challenges with rapid cash burn - a critical factor for investors monitoring its product development progress.
"Dr. Hirsh’s expertise in interventional cardiology procedures directly supports our CBGM’s unique intravascular placement," said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack, in a press release statement.
The company is currently advancing through clinical trials, including a long-term OUS (outside United States) early feasibility study and an upcoming US pilot study.
The CBGM remains an investigational device limited by federal law to investigational use, according to the company.
In other recent news, Glucotrack, Inc. reported positive outcomes from its first human trial of an implantable Continuous Blood Glucose Monitor (CBGM), achieving a Mean Absolute Relative Difference (MARD) of 7.7% and meeting all primary and secondary endpoints. This study, conducted in São Paulo, Brazil, involved participants with Type 1 or Type 2 diabetes on intensive insulin therapy. Additionally, Glucotrack announced a 1-for-60 reverse stock split, which reduced the number of outstanding shares significantly, with adjustments made to stock options and warrants. The reverse split took effect on June 16, 2025, and the company’s shares continue to trade under the same ticker symbol with a new CUSIP number.
In other developments, Glucotrack appointed CBIZ CPAs P.C. as its new independent registered public accounting firm for the fiscal year ending December 31, 2025, replacing Grant Thornton Israel. The company also welcomed Dr. Victoria E. Carr-Brendel to its Board of Directors, who brings a wealth of experience in medical devices and implantable technologies. Dr. Carr-Brendel’s expertise is anticipated to aid in advancing Glucotrack’s strategic and clinical goals. These recent developments highlight Glucotrack’s ongoing efforts to enhance its technological offerings and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.